About Vitarka Therapeutics

Vitarka Therapeutics has developed EndoPore, a targeted non-viral delivery platform utilizing engineered pore-forming proteins to facilitate the intracellular delivery of therapeutic cargoes such as siRNA, ASO, and peptides. This technology significantly enhances cargo delivery efficiency, achieving up to 80% cytosolic delivery, which addresses the low efficacy of traditional lipid nanoparticle systems in treating late-stage cancers and neurodegenerative diseases.

```xml <problem> Traditional methods of intracellular drug delivery, such as lipid nanoparticles, often exhibit low efficacy in delivering therapeutic cargoes like siRNA, ASO, and peptides into the cytosol of target cells. This limitation hinders the treatment of late-stage cancers and neurodegenerative diseases, where effective intracellular delivery is crucial. </problem> <solution> Vitarka Therapeutics has developed EndoPore, a targeted non-viral delivery platform that utilizes engineered pore-forming proteins to facilitate the intracellular delivery of therapeutic cargoes. EndoPore enhances cargo delivery efficiency, achieving up to 80% cytosolic delivery, a significant improvement over traditional lipid nanoparticle systems. The platform's modular design allows it to carry a variety of cargoes into different cell types, including tumor cells, motor neurons, and sensory neurons. By specifically targeting and binding to cell surface receptors, EndoPore enters cells and releases its therapeutic cargo into the cytosol through a translocation channel in the endosomal membrane. </solution> <features> - Engineered pore-forming proteins for targeted intracellular delivery - High cytosolic delivery efficiency (up to 80%) compared to lipid nanoparticles (less than 1%) - Modular design adaptable to various therapeutic cargoes (siRNA, ASO, peptides) - Cell-binding domain validated in human clinical trials - Demonstrated efficacy in cell and animal-based disease-relevant models - Scalable production processes ready for GMP-grade transfer, yielding several grams of EndoPore per liter of culture - Specific targeting and binding to cell surface receptors for cellular entry - Formation of a translocation channel in the endosomal membrane for cargo release into the cytosol </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing therapeutics for oncology, neuroscience, pain management, and neurodegenerative diseases. </target_audience> ```

What does Vitarka Therapeutics do?

Where is Vitarka Therapeutics located?

Vitarka Therapeutics is based in London, United Kingdom.

How much funding has Vitarka Therapeutics raised?

Vitarka Therapeutics has raised 1600000.

Location

London, United Kingdom

Funding

1600000

Employees

5 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Vitarka Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

vitarka.co.uk 700+

Crunchbase

London, United Kingdom

Funding

Estimated Funding

$1M+

Team (5+)

No team information available.

Company Description

Problem

Traditional methods of intracellular drug delivery, such as lipid nanoparticles, often exhibit low efficacy in delivering therapeutic cargoes like siRNA, ASO, and peptides into the cytosol of target cells. This limitation hinders the treatment of late-stage cancers and neurodegenerative diseases, where effective intracellular delivery is crucial.

Solution

Vitarka Therapeutics has developed EndoPore, a targeted non-viral delivery platform that utilizes engineered pore-forming proteins to facilitate the intracellular delivery of therapeutic cargoes. EndoPore enhances cargo delivery efficiency, achieving up to 80% cytosolic delivery, a significant improvement over traditional lipid nanoparticle systems. The platform's modular design allows it to carry a variety of cargoes into different cell types, including tumor cells, motor neurons, and sensory neurons. By specifically targeting and binding to cell surface receptors, EndoPore enters cells and releases its therapeutic cargo into the cytosol through a translocation channel in the endosomal membrane.

Features

Engineered pore-forming proteins for targeted intracellular delivery

High cytosolic delivery efficiency (up to 80%) compared to lipid nanoparticles (less than 1%)

Modular design adaptable to various therapeutic cargoes (siRNA, ASO, peptides)

Cell-binding domain validated in human clinical trials

Demonstrated efficacy in cell and animal-based disease-relevant models

Scalable production processes ready for GMP-grade transfer, yielding several grams of EndoPore per liter of culture

Specific targeting and binding to cell surface receptors for cellular entry

Formation of a translocation channel in the endosomal membrane for cargo release into the cytosol

Target Audience

The primary target audience includes pharmaceutical companies and research institutions focused on developing therapeutics for oncology, neuroscience, pain management, and neurodegenerative diseases.